A short cut review was carried out to establish whether Rivaroxaban is superior to warfarin in the management of pulmonary embolism. Three studies were directly relevant to the question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of these papers are tabulated. The clinical bottom line is that Rivaroxaban is a promising alternative to warfarin in the management of pulmonary embolism.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.